DAFTAR PUSTAKA

1. Fukayama M, Goldblum JR MMLA, editor. Gastrointestinal stromal tumor. In: Digestive System Tumours WHO Classification of Tumours. fifth edit. Internastional Agency for Research on Cancer World Health Organization; 2019. p. 436–43.

2. Tan D, Lauwers GY. Gastrointestinal Stromal Tumor. In: Allen PTC and TC, editor. Advances in Surgical Pathology: Gastric Cancer. Philadelphia, USA: Wolters Kluwer; 2012. p. 1–348.

3. Rohit Kumar, Satyendra KT, Puneet AK. Gastrointestinal stromal tumor: Review. Galore Int J Heal Sci Res. 2022;Volume 7(1).

4. Ahmed M. Recent advances in the management of gastrointestinal stromal tumor. World J Clin Cases. 2020;8(15):3142–55.

5. Azizah N, Rusmin SA, Subandrate. Hubungan Antara Karakter Klinikopatologik dengan Grup Prognostik WHO pada Pasien Gastrointestinal Stromal Tumor di RSUP Dr. Mohammad Hoesin, Palembang | Majalah Patologi Indonesia. Maj Patol Indones. 2021;30(1):219–26.

6. Aliska G, Novianti H, Angraini D, Liana N, Nova R, Rustam E. The Profile of Gastrointestinal Stromal Tumors (GISTs) at M . Djamil General Hospital Padang , Indonesia : A Descriptive Study on 28 Patients. Front Healthc Res. 2024;1(1).

7. Gheorghe G, Bacalbasa N, Ceobanu G, Ilie M, Enache V, Constantinescu G, et al. Gastrointestinal stromal tumors-a mini review. J Pers Med. 2021;11(8).

8. Juan Rosai and Ackerman. Stomach: Gastrointestinal Stromal Tumor in Surgical Pathology. In: Rosai J, editor. Surgical Pathology. Tenth Edit. New York: Elsevier; 2011. p. 693–6.

9. R.Goldblum J, editor. Gastrointestinal and Liver Pathology. Second. Vol. 11, Sustainability (Switzerland). Elsevier Saunders; 2019. 1–14 p.

10. Unk M, Jezeršek Novaković B, Novaković S. Molecular Mechanisms of Gastrointestinal Stromal Tumors and Their Impact on Systemic Therapy Decision. Cancers (Basel). 2023;15(5).

11. Wu CE, Tzen CY, Wang SY, Yeh CN. Clinical diagnosis of gastrointestinal stromal tumor (Gist): From the molecular genetic point of view. Cancers (Basel). 2019;11(5):1–15.

12. Jaypuriya DA, Gupta DGN, Faujdar DM. Study from Tertiary Care Centre Elucidating the Role of CD 117 & DOG 1 Antibodies in Diagnosis of Gastrointestinal Stromal Tumors. Int J Res Rev. 2022;9(8):678–89.

13. Sun XW, Feng ZJ, Huang P, Hao W, Sui XL. Expression of DOG1, CD117 and PDGFRA in gastrointestinal stromal tumors and correlations with clinicopathology. Asian Pacific J Cancer Prev. 2012;13(4):1389–93.

14. Kunjunny RP, Ponnappan MC. Expression of DOG1, CD117 & PDGFRA in Gastrointestinal Stromal Tumours and Correlations with Clinicopathological Features & Risk Assessment. J Evol Med Dent Sci. 2022;11(1):103–8.

15. Cesar Serrano, Javier Martin, Jose manuel JA. 2023 GEIS Guidelines for Gastrointestinal Stromal Tumors. Ther Adv Med Oncol. 2023;15:1–18.

16. Cao L, Lin C, Liu Y, Sui C, Li Z, Chen L, et al. Clinical characteristics and prognostic analysis of postoperative recurrence or metastasis of low-risk gastrointestinal stromal tumors. World J Surg Oncol. 2024;22(1):1–9.

17. Robert D. Odze JRG. Surgical Pathology of the GI Tract, Liver, Biliary Tract and Pancreas. Third. Philadelphia: Elsevier Saunders; 2015. 822–830 p.

18. Li J, Zhang H, Chen Z, Su K. Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a Chinese population. Int J Clin Exp Pathol. 2015;8(12):15969–76.

19. Abdellateif MS, Bayoumi AK, Mohammed MA. c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights. Onco Targets Ther. 2023;16(September):785–99.

20. Ma A, Bensadoun R, Aa A, Ah F, Ama A. The Association Between Ki-67 Proliferation Index and Disease Progression in Gastro Intestinal Stromal Tumors : A Retrospective Study Introduction : 2024;2024(1):1–13.

21. Li J, Wang AR, Chen XD, Pan H, Li SQ. Ki67 for evaluating the prognosis of gastrointestinal stromal tumors: A systematic review and meta-analysis. Oncol Lett. 2022;23(6):1–7.

22. Fred T Bosman, Fatima Carneiro, Ralph H Hruban NDT. WHO Classification of Tumours of the Digestive System. 4th ed. France: Internastional Agency for Research on Cancer World Health Organization; 2010. 74–115 p.

23. Dowgiałło-Gornowicz N, Sztaba K, Lech P, Botulińska A, Michalik M. The incidence of gastrointestinal stromal tumors in obese patients—a large single center experience. Med. 2021;57(11).

24. Sterbis E, Baker J, Rosenbluth A, Buwen J, Beekley AC, Tichansky DS, et al. Incidence of Gastrointestinal Stromal Tumors Is Drastically Increased In Patients with Morbid Obesity. J Surg. 2017;2(1):1–5.

25. López-Pingarrón L, Almeida H, Soria-Aznar M, Reyes-Gonzales MC, Rodríguez-Moratinos AB, Muñoz-Hoyos A, et al. Interstitial Cells of Cajal

and Enteric Nervous System in Gastrointestinal and Neurological Pathology, Relation to Oxidative Stress. Curr Issues Mol Biol. 2023;45(4):3552–72.

26. Dermawan JK, Rubin BP. Molecular Pathogenesis of Gastrointestinal Stromal Tumor: A Paradigm for Personalized Medicine. Annu Rev Pathol Mech Dis. 2021;17:323–44.

27. Bauer S, George S, von Mehren M, Heinrich MC. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor. Front Oncol. 2021;11(July):1–11.

28. Mathias-Machado MC, de Jesus VHF, de Carvalho Oliveira LJ, Neumann M, Peixoto RD. Current Molecular Profile of Gastrointestinal Stromal Tumors and Systemic Therapeutic Implications. Cancers (Basel). 2022;14(21):1–16.

29. Fudalej MM, Maria A, Kozakiewicz B. Improved understanding of gastrointestinal stromal tumors biology as a step for developing new diagnostic and therapeutic schemes (Review). 2021;(15):1–8.

30. Lino-Silva LS, Segales-Rojas P, Aguilar-Cruz E, Salcedo-Hernández RA, Zepeda-Najar C. Gastrointestinal Stromal Tumors Risk of Recurrence Stratification by Tumor Volume is a Best Predictor Compared with Risk Based on Mitosis and Tumor Size. J Gastrointest Cancer. 2019;50(3):513–8.

31. Greco A, Rossi S, Ruffolo C, Pauletti B, Dei Tos AP, Morana G, et al. Evidence for improvements to risk stratification in high-risk gastrointestinal stromal tumor patients. Gastrointest Cancer Targets Ther. 2018;Volume 8:25–36.

32. Husain NE, Osman IM, Khalid A. Clinicopathological, immunohistochemical, molecular-genetic and risk profile of gastrointestinal stromal tumor in a cohort of Sudanese patients. Afr Health Sci [Internet]. 2023;23(1):444–58. Available from: https://doi.org/10.4314/abs.v23i1.47

33. Sleisenger and Fordtran's. Gastrointestinal and Liver Disease. 10 th Edit. Mark Feldman LS and LJ, editor. Vol. 1. New York: Elsevier Saunders; 2016.

34. Serrano C, Álvarez R, Antonio J, Gloria C, Jerónimo M, García M, et al. SEOM - GEIS clinical guideline for gastrointestinal stromal tumors (2022). Clin Transl Oncol. 2023;25(9):2707–17.

35. John M. Kane, Mary Anne Bergman HS and LEH. NCCN Guidelines Insight Gastrointestinal Stromal Tumors , Version 2 . 2022. J Natl Compr Cancer Netw. 20(11):1204–14.

36. Eskitzis P, Michou V, Theoti R, Antoniou A, Tsavlis D, Anestakis D. Unraveling Gastric and Small Intestine Gastrointestinal Stromal Tumors: A Review of Our Current Knowledge. Gastrointest Disord. 2024;6(4):842–57.

37. Pathania S, Pentikäinen OT, Singh PK. A holistic view on c-Kit in cancer: Structure, signaling, pathophysiology and its inhibitors. Biochim Biophys Acta - Rev Cancer. 2021;1876(2).

38. Sheikh E, Tran T, Vranic S, Levy A, Bonfil RD. Role and significance of c-KIT receptor tyrosine kinase in cancer: A review. Bosn J Basic Med Sci. 2022;22(5):683–98.

39. Gilreath JA, Tchertanov L, Deininger MW. Novel approaches to treating advanced systemic mastocytosis. Clin Pharmacol Adv Appl. 2019;11:77–92.

40. Braicu C, Buse M, Busuioc C, Drula R, Gulei D, Raduly L, et al. A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer. mdpi J cancer. 2019;11.

41. Hu Q, Bian Q, Rong D, Wang L, Song J, Huang HS, et al. JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens. Front Bioeng Biotechnol. 2023;11(February):1–24.

42. Zhou S, Abdihamid O, Tan F, Zhou H, Liu H, Li Z, et al. KIT mutations and expression: current knowledge and new insights for overcoming IM resistance in GIST. Cell Commun Signal. 2024;22(1):1–21.

43. Budipramana VS, . S, Fauziah D. Correlation between GIST positive CD117 with EGFR expression based on tumor size and mitotic index. Int J Clin Diagnostic Pathol. 2019;2(2):85–9.

44. Foster BM, Zaidi D, Young TR, Mobley ME, Kerr BA. CD117/c-kit in cancer stem cell-mediated progression and therapeutic resistance. Biomedicines. 2018;6(1):1–19.

45. Huang WK, Wu CE, Wang SY, Chang CF, Chou WC, Chen JS, et al. Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges. Curr Treat Options Oncol. 2022;23(9):1303–19.

46. Vallilas C, Sarantis P, Kyriazoglou A, Koustas E, Theocharis S, Papavassiliou AG, et al. Gastrointestinal stromal tumors (GISTS): Novel therapeutic strategies with immunotherapy and small molecules. Int J Mol Sci. 2021;22(2):1–13.

47. Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, et al. Survival Outcomes Associated with 3 Years vs 1 Year of Adjuvant Imatinib for Patients with High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial after 10-Year Follow-up. JAMA Oncol. 2020;6(8):1241–6.

48. Güler B, Özyılmaz F, Tokuç B, Can N, Taştekin E. Histopathological features of gastrointestinal stromal tumors and the contribution of DOG1 expression to the diagnosis. Balkan Med J. 2015;32(4):388–96.

49. Rasheed MW, Abiodun AE, Eziagu UB, Idowu NA, Kabiru A, Adegboye TA, et al. Clinicopathological and immunohistochemical characterization of gastrointestinal stromal tumour at four tertiary health centers in Nigeria using CD117, DOG1, and human epidermal growth factor receptor-2 biomarkers. Ann Afr Med. 2023;22(4):501–7.

50. Abbas F, Besina S, Farooq S, Bhat GM, Ashraf S, Latief M. Role of novel marker discovered on gastrointestinal stromal tumor 1 in evaluation of gastrointestinal stromal tumors. Indian J Med Paediatr Oncol. 2021;40(2):244–8.

51. Menon SS, Guruvayoorappan C, Sakthivel KM, Rasmi RR. Ki-67 protein as a tumour proliferation marker. Clin Chim Acta. 2019;491(November 2018):39–45.

52. Zhou Y, Hu W, Chen P, Abe M, Shi L, Tan SY, et al. Ki67 is a biological marker of malignant risk of gastrointestinal stromal tumors. Med (United States). 2017;96(34):1–5.

53. Xiaoming Sun and Paul D. Kaufman. Ki-67 : more than a proliferation marker. Chromosom J. 2018;127(2):175–86.

54. Tian J, Chen W. Prediction of Ki-67 expression and malignant potential in gastrointestinal stromal tumors: novel models based on CE-CT and serological indicators. BMC Cancer. 2024;24(1).

55. Xiao L, Zhang Y, Wang Y, Liu L, Pan Y. The relationship between Ki-67 expression and imaging signs and pathological features in GISTs. Front Surg. 2023;10(March):1–10.

56. Kadado KJ, Abernathy OL, Salyers WJ, Kallail KJ. Gastrointestinal Stromal Tumor and Ki-67 as a Prognostic Indicator. Cureus. 2022;14(1):1–4.

57. Yulianti H, Hernowo BS. Hubungan antara Imunoekspresi Ki-67 dan Risiko Agresivitas Tumor pada Gastrointestinal Stromal Tumor. Maj Kedokt Bandung. 2015;47(4):231–6.

58. Dongfeng Tan GYL. Advances in surgical pathology: Gastric cancer. Allen PTC and TC, editor. Advances in Surgical Pathology: Gastric Cancer. Houston, Texas: Wolter Kluwer; 2012. 1–348 p.

59. Zhang T, Liang C, Su D. Histopathologic and Immunohistochemical Analysis of 66 Cases of Gastrointestinal Stromal Tumor. J Biosci Med. 2023;11(06):140–7.

60. Wang M, Xue A, Yuan W, Gao X, Fu M, Fang Y, et al. Clinicopathological Features and Prognosis of Small Gastric Gastrointestinal Stromal Tumors (GISTs). J Gastrointest Surg. 2019;23(11):2136–43.

61. Şahın S, Ekinci Ö, Seçkın S, Dursun A. The diagnostic and prognostic utility

of DOG1 expression on gastrointestinal stromal tumors. Turk Patoloji Derg. 2017;33(1):1–8.

62. Liu T, Lin G, Peng H, Huang L, Jiang X, Li H, et al. Clinicopathological characteristics and prognosis of gastrointestinal stromal tumors containing air-fluid levels. PLoS One [Internet]. 2021;16(12 December):1–13. Available from: http://dx.doi.org/10.1371/journal.pone.0261566

63. Jia G, Li X. Survival trends of gastrointestinal stromal tumor in real-world settings: a population-based retrospective study. Pathol Oncol Res. 2025;31(March):1–11.

64. Yana Miroshnichenko. immunohistochemical Features of Gastrointestinal Stromal Tumors and Their Role For Differential Diagnosis and Prognosis. Heal Sci J [Internet]. 2021;(6). Available from: doi: 10.21303/2504-5679.2021.002183

65. Kramer K, Knippschild U, Mayer B, Bögelspacher K, Spatz H, Henne-Bruns D, et al. Impact of age and gender on tumor related prognosis in gastrointestinal stromal tumors (GIST). BMC Cancer. 2015;15(1):1–10.

66. Ashindoitiang JA, Nwagbara VIC, Ugbem TI, Enya NJ, Aniebo IO, Ekong JC, et al. Extra-gastrointestinal stromal tumour of the lesser omentum presenting as a massive intra-abdominal swelling: A case report and literature review. Rare Tumors. 2024;16:1–5.

67. Feng Y, Liu L. Clinicopathological characteristics and long-term prognosis of peritoneal and retroperitoneal gastrointestinal stromal tumors. Surg Endosc [Internet]. 2025;(0123456789). Available from: https://doi.org/10.1007/s00464-025-11600-z

68. Khan TM, Verbus EA, Rossi AJ, Hernandez JM, Davis JL, Coakley BA, et al. Patient demographics, clinicopathologic features, and outcomes in wild-type gastrointestinal stromal tumor: a national cohort analysis. Sci Rep [Internet]. 2022;12(1):1–8. Available from: https://doi.org/10.1038/s41598-022-09745-1

69. Radu P, Zurzu M, Tigora A, Paic V, Bratucu M, Garofil D, et al. Gastrointestinal stromal tumors : a focus on the impact of interstitial cells of Cajal in disease development. 2024;11(2):412–9.

70. Tepeoğlu M, Özgün G, Tunca MZ, Tezcaner T, Özdemir BH. Gastrointestinal stromal tumors: A clinicopathological and immunohistochemical study of 65 cases. Turk Patoloji Derg. 2018;34(3):207–14.

71. Fatimah F, Mustokoweni S, Rahniayu A. Analisis Ekspresi CD117 dan Ki-67 pada Tumor Phyllodes Benign, Borderline dan Malignant. 2018;27(1).

72. Findik S, Kanyilmaz G. GastroClinicopathologic Characteristics of Gastrointestinal Stromal Tumors and Prognostic Importance of Ki-67 Labeling Index: May be a New Prognostic Marker. Konuralp Tıp Derg. 2022;14(2):323–8.

73. Manchala L, Kotta DR, Somalwar SB, Nagamuthu EA. Cd117, Dog1 and Ki67 Expression in Gastrointestinal Stromal Tumours. J Evid Based Med Healthc. 2017;4(75):4417–22.


UNIVERSITAS ANDALAS
UNTUK
KEDJAJAAN
BANGSA